Express News | Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an Asco 2024 Abstract
10-Q: Quarterly report
Express News | Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
Express News | Interpace Biosciences Q1 Gross Profit USD 6.071 Million
Express News | Interpace Biosciences Q1 Operating Expenses USD 5.197 Million
Express News | Interpace Biosciences Q1 Revenue USD 10.273 Million
Express News | Interpace Biosciences Q1 Net Income USD 468 Thousand
Interpace Biosciences Announces Preliminary Q4 Revenue of $10.3M
Interpace Biosciences GAAP EPS of $0.09, Revenue of $11.03M
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN Reimbursement
Interpace Expects to Stop Offering PancraGEN Test Due to CMS Decision to End Reimbursement as of July 17, 2023
Interpace Biosciences GAAP EPS of $0.10, Revenue of $9.8M
Express News | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q1 Revenue $9.8M
Interpace Biosciences GAAP EPS of -$0.33, Revenue of $8.33M
Express News | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $8.3M
Interpace Biosciences GAAP EPS of $3.35, Revenue of $8.2M
Express News | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q3 Revenue $8.19M
Express News | Interpace Biosciences CFO Thomas Freeburg Resigns
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.
Interpace Biosciences GAAP EPS of -$0.53, revenue of $10.38M
No Data